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ABSTRACT
Objective Patients with Niemann–Pick disease type
C1 (NPC1), a lysosomal lipid storage disorder that
causes neurodegeneration and liver damage, can present
with IBD, but neither the signiﬁcance nor the functional
mechanism of this association is clear. We studied
bacterial handling and antibacterial autophagy in
patients with NPC1.
Design We characterised intestinal inﬂammation in 14
patients with NPC1 who developed IBD. We investigated
bacterial handling and cytokine production of NPC1
monocytes or macrophages in vitro and compared
NPC1-associated functional defects to those caused by
IBD-associated nucleotide-binding oligomerization
domain-containing protein 2 (NOD2) variants or
mutations in X-linked inhibitor of apoptosis (XIAP).
Results Patients with the lysosomal lipid storage
disorder NPC1 have increased susceptibility to early-
onset ﬁstulising colitis with granuloma formation,
reminiscent of Crohn’s disease (CD). Mutations in NPC1
cause impaired autophagy due to defective
autophagosome function that abolishes NOD2-mediated
bacterial handling in vitro similar to variants in NOD2 or
XIAP deﬁciency. In contrast to genetic NOD2 and XIAP
variants, NPC1 mutations do not impair NOD2-receptor-
interacting kinase 2 (RIPK2)-XIAP-dependent cytokine
production. Pharmacological activation of autophagy can
rescue bacterial clearance in macrophages in vitro by
increasing the autophagic ﬂux and bypassing defects in
NPC1.
Conclusions NPC1 confers increased risk of early-
onset severe CD. Our data support the concept that
genetic defects at different checkpoints of selective
autophagy cause a shared outcome of CD-like
immunopathology linking monogenic and polygenic
forms of IBD. Muramyl dipeptide-driven cytokine
responses and antibacterial autophagy induction are
parallel and independent signalling cascades
downstream of the NOD2-RIPK2-XIAP complex.
Signiﬁcance of this study
What is already known on this subject?
▸ Defects in host–bacterial interactions cause
IBD.
▸ Defects in autophagy are associated with
delayed elimination of intracellular bacteria and
intestinal inﬂammation, as observed in Crohn’s
disease.
▸ Monogenic forms of IBD inform about
non-redundant pathways in the mucosal
immune system.
What are the new ﬁndings?
▸ Mutations in Niemann–Pick disease type C1
(NPC1) predispose to early-onset IBD with
Crohn’s disease phenotype and granuloma
formation.
▸ NPC1 defects impair the elimination of
intracellular bacteria in macrophages due to
dysfunctional autophagy.
▸ NPC1-associated intestinal inﬂammation shares
a functional defect of impaired antibacterial
autophagy with Crohn’s disease-associated
variants in nucleotide-binding oligomerization
domain-containing protein 2 and mutations in
X-linked inhibitor of apoptosis, a cause of
monogenic IBD, but muramyl
dipeptide-initiated cytokine production is not
affected in patients with NPC1.
▸ Rescue of lysosomal lipid storage defect in
NPC1 macrophages by US Food and Drug
Administration-approved cyclodextrin does not
restore antibacterial autophagy, whereas
autophagy induction by chlorpromazine can
rescue the impaired bacterial handling
phenotype.
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INTRODUCTION
Niemann–Pick type C (NPC) is a neurodegenerative lysosomal
storage disorder1 associated with defects in lysosomal calcium
homeostasis and lipid trafﬁcking.2 It is caused by mutations in
the NPC1 or NPC2 genes.1 The accumulation of unesteriﬁed
cholesterol and multiple sphingolipids in the late endosomal/
lysosomal system causes neurological and visceral symptoms. So
far, no speciﬁc immune dysfunction has been linked to NPC.
However, a high proportion of patients develop airway infec-
tions.3 Two cases of Crohn’s-like disease were reported in
patients with genetically conﬁrmed NPC1 mutations.4 5
IBD is a multifactorial disorder with genetic susceptibility,
immunological predisposition and environmental triggers.6 7 To
date, >150 genetic loci have been linked to IBD by association
studies.8 Variants in genes that affect bacterial handling (such as
nucleotide-binding oligomerization domain-containing protein 2
NOD2) and autophagy (such as ATG16L1 or IRGM) are asso-
ciated with polygenic IBD. Variants in NOD2 are the strongest
genetic risk factor for Crohn’s disease (CD).7 9 10 NOD2 plays
a key role in bacterial handling in dendritic cells and in the epi-
thelium.11–13
In addition to polygenic IBD comprising CD and ulcerative
colitis (UC), there are an increasing number of monogenic disor-
ders presenting with IBD and highlighting a role of bacterial
handling in innate immune cells.14–16 In male patients, muta-
tions in the gene encoding X-linked inhibitor of apoptosis
(XIAP) cause an immune-dysregulation syndrome characterised
by haemophagocytic lymphohistiocytosis and further inﬂamma-
tory complications. Notably, one-ﬁfth of patients with XIAP
deﬁciency develop severe CD-like granulomatous colitis.17–20
More recently, the ubiquitin (Ub) ligase XIAP emerged as an
essential signal transducer downstream of the cytosolic sensor
NOD2.21 22 Following activation of NOD2 by muramyl dipep-
tide (MDP), a bacterial cell wall product, XIAP binds and ubi-
quitinates the adapter protein receptor-interacting kinase 2
(RIPK2) to facilitate nuclear factor (NF)-κB signalling and cyto-
kine production.23 Multiple Ub-dependent signalling events
regulate NOD2 activity and converge on the adapter protein
RIPK2.24 25
Here, we report that antibacterial autophagy initiated by the
NOD2-RIPK2-XIAP pathway is a key defect in disorders pre-
senting with granulomatous intestinal inﬂammation and this
defect can be independent of MDP-mediated cytokine produc-
tion. Based on a case series of 14 patients with NPC1 mutations
who developed early-onset CD-like disease with granuloma for-
mation and patients with mutations in NOD2 and XIAP, we
provide evidence of a shared defect of degradation of bacteria,
such as Salmonella enterica serovar typhimurium (S. typhimur-
ium) and CD-associated adherent-invasive Escherichia coli
(AIEC). In contrast to patients with NOD2 and XIAP variants,
MDP-induced cytokine secretion via NOD2 and XIAP is intact
in patients with NPC1. Our results suggest that in NPC1 autop-
hagosomal maturation rather than lysosomal dysfunction affects
autophagic elimination of intracellular bacteria. In our model,
dysregulated cytokine response is the consequence of incom-
plete bacterial clearance and pharmaceutical induction of autop-
hagy can restore bacterial killing, suggesting a potential
therapeutic strategy.
MATERIALS AND METHODS
Research subjects
Participating centres contributed anonymised patient data or
blood samples with local ethics. Historic patient notes were
only reviewed if written informed consent for research was
available. Adult patients with NPC were able to give full
informed consent. Healthy control blood samples were obtained
from healthy volunteer donors (healthy control group I) or as
leucocyte cones (healthy control group II) from UK blood
donor bank.
Patients with NPC1
NPC1-IBD case-ﬁnding was performed in several European and
US centres, specialised in NPC patient care. In addition, search-
ing the ehealthMe database (http://www.ehealthme.com) for
NPC and IBD/colitis/CD revealed six patient reports (range 2–
19 years) that allowed retrieval of adverse outcome reports of
the Center of Disease Control (Atlanta, USA) reporting IBD-like
immunopathology in patients with NPC1 who had received
miglustat treatment. Phenotype data were captured using a
structured survey. For functional experiments, blood samples
were obtained from six patients with NPC1 (two female,
median age 29 years, range 13–50 years, three patients on
miglustat). Among those, four patients did not have IBD.
Further details are provided in online supplementary materials.
NOD2 and XIAP patients
Twenty-six IBD patients with wild-type (WT) or variant NOD2
genotype were recruited from the Oxford IBD cohort study,
which is a single-centre prospective cohort study investigating
patients with IBD across all ages (Oxford IBD cohort study,
manuscript in preparation). Carriers of NOD2 polymorphisms
were identiﬁed by Immunochip. Eight individuals with genetic-
ally conﬁrmed XIAP mutations were recruited from centres for
immunodeﬁciency in Oxford and London, UK, and Toronto,
Canada. For patient details, see online supplementary tables.
Differentiation and culture of cells
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll gradient centrifugation. Monocyte-derived macrophages
(MDM) were differentiated from the adherent fraction of
PBMC over 5 days in RPMI-1640 medium supplemented with
10% fetal calf serum (Sigma-Aldrich) and 100 ng/mL macro-
phage colony-stimulating factor (M-CSF) (R&D Systems).
Stimuli and cytokines
PBMC or MDM were stimulated with MDP (10 mg/mL), lipi-
dated L18-MDP (200 ng/mL), inactive D-D isomer of MDP
(10 mg/mL), Flagellin from S. typhimurium (100 ng/mL),
Pam3CSK4 (100 ng/mL, all Invivogen), Lipopolysaccharide
(LPS) from Salmonella minnesota R595 (20–200 ng/mL, Enzo),
interleukin (IL)-10 (20 ng/mL), interferon (IFN)-γ (50 ng/mL)
or tumour necrosis factor (TNF) (10 ng/mL, all Peprotech).
Lipidation of MDP (L18-MDP) allows reduction of MDP con-
centration in stimulation studies.
Signiﬁcance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ Patients with NPC1 and GI problems should be screened for
Crohn’s disease-like intestinal inﬂammation.
▸ Induction of autophagy is a potential therapeutic strategy to
overcome genetic autophagy defects.
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Chemical compounds
Small-molecule inhibitors were added to cell culture medium
1 h prior to stimulation. ML-130 (5 mM) and ponatinib
(50 nM) were purchased from Selleck Chemical. Compound
21a (XIAP-Cp-21a, 1–2.5 mM) was kindly provided by
TetraLogics Pharmaceuticals.26–28 To induce the lysosomal lipid
storage phenotype in MDM/PBMC, cells were pre-incubated
with 2 mg/mL U18666A (Sigma-Aldrich) for 48/24 h. Other
compounds were baﬁlomycin A1 (50 nM, Enzo Life Sciences),
2-hydroxypropyl-β-cyclodextrin (0.5–2%, Sigma-Aldrich),
chlorpromazine (1–10 μg/mL, Merck Millipore), rapamycin (1–
10 mM, Cayman Chemical), Torin 1 (10 mM, Tocris),
D-(+)-trehalose dihydrate (100 mM, Sigma-Aldrich) and miglu-
stat (4–400 mM, Tocris).
Intracellular ﬂow cytometry
Measurement and quantiﬁcation of intracellular TNF in mono-
cytes was performed as described previously29 and as detailed in
online supplementary methods.
Gentamicin protection assay
Bacterial uptake, intracellular survival and replication were tested
with the following strains: Salmonella enterica serovar typhimur-
ium (S. typhimurium)-expressing green-ﬂuorescent protein
(GFP) (NCTC 12023) and CD-associated AIEC reference strain
LF82.30 Bacteria were freshly grown and used at mid-log phase.
MDM in 96-well ﬂat bottom plates were pretreated with inhibi-
tors and subsequently stimulated for 2 h before infection at a
multiplicity of infection of 10 bacteria per cell. One hour post
infection, new complete medium supplemented with 100 mg/mL
gentamicin was added. At 3 h post infection, MDM were washed
and lysed in 1% Triton X-100 in deionised water to determine
the number of colony-forming units (CFU) recovered from the
lysed macrophages. For each donor, conditions were tested in
three parallel infection experiments and results are normalised to
individual mean CFU of unstimulated or vehicle-treated condi-
tion. Results per donor are shown.
Confocal microscopy
See online supplementary methods.
Puriﬁcation of endogenous Ub conjugates
Puriﬁcation of endogenous Ub conjugates was performed with
Tandem Ubiquitin Binding Entities (TUBE) as described previ-
ously23 and as outlined in online supplementary methods.
Immunoblotting
See online supplementary methods.
Statistical analysis
Data analysis was performed using GraphPad Prism V.5.00
(GraphPad Software, San Diego, California, USA). Data were
compared using two-sided Mann–Whitney U test. Post hoc
testing with analysis of variance and post-test correction with
Bonferroni (comparisons of MDP-mediated effects) or Dunnett
(multiple comparisons to one single control) conﬁrmed pre-
sented statistical signiﬁcance. Categorical data were compared
using two-sided Fisher’s exact test and conﬁdence intervals cal-
culated according to the Wald equation. p<0.05 was considered
signiﬁcant (*p<0.05, **p<0.01, ***p<0.001).
RESULTS
Patients with symptomatic NPC1 develop early-onset
CD-like intestinal inﬂammation with granuloma
We studied a cohort of 14 patients with defects in NPC1 who
presented with severe CD-like intestinal inﬂammation and mul-
tinucleated granuloma on histopathology (ﬁgure 1A, B, table 1
and online supplementary table S1). Granuloma were present in
7 of the 14 patients and foam cell macrophages, indicating lipid
storage were present in some (ﬁgure 1B).
In patients with NPC1, the mean age at IBD diagnosis was
12.8±8.6 years (range 3.6–32.2 years), which is signiﬁcantly
earlier compared with an unselected IBD cohort (ﬁgure 1C).
The diagnosis of NPC1 preceded the onset of IBD in all cases
and included typical signs and symptoms consistent with
Figure 1 Niemann–Pick disease type C1 (NPC1) is associated with early-onset Crohn’s-like immunopathology. (A) Evidence of multiple aphthous
lesions on colonoscopy and severe perianal disease complicated by ﬁstulas (arrow head). (B) Colonic biopsies of patients with NPC1-IBD showing
large granulomas, polymorphic cell inﬁltrate (left images, H&E stain) and foam cell macrophages (right image, Periodic acid–Schiff (PAS) stain). (C)
Age at IBD diagnosis comparing patients with NPC1-IBD (n=14) with Oxford IBD cohort study (n=2113). (D) Frequency of IBD diagnosis made in the
two cohorts. Fisher’s exact test, ***p<0.001. (E) NPC1 schematic showing mutations identiﬁed in NPC1-IBD cohort. Circles: female patients;
squares: male patients.
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NPC1.1 Clinical features of IBD were weight loss, diarrhoea,
rectal bleeding, anogenital ulceration, ﬁssures and ﬁstulas
(table 1). Perianal disease was noted in 11 of 14 patients. The
diagnosis of IBD was conﬁrmed by endoscopy and biopsy in all
cases. Eighty-six per cent of patients (12/14) were diagnosed
with CD-like and two patients with IBD unclassiﬁed, conﬁrming
a signiﬁcant association of NPC with CD compared with an
unselected IBD cohort (ﬁgure 1D).
Treatment of patients with NPC1 with intestinal inﬂammation
involved steroids, 5-aminosalicylates, azathioprine and exclusive
enteral nutrition. Step-up therapy with inﬂiximab was required in
six patients (50%); two patients underwent colectomy and stoma
formation (table 1). Treatment with miglustat, an European
Medicines Agency-approved therapy for NPC133 that reduces
lipid storage and delays disease progression, was not associated
with onset of IBD-like inﬂammation (see online supplementary
ﬁgure S1). The spectrum of genetic defects in NPC1-IBD does not
suggest a speciﬁc genotype–phenotype association (ﬁgure 1E).
Bacterial killing in macrophages is MDP-dependent
We initially assessed whether NPC1 is involved in
gene-interaction or protein-interaction networks that include
established IBD loci8 or known monogenic IBD variants.15 We
could not predict those interactions (see online supplementary
ﬁgure S2). Prompted by the ﬁnding of large multinucleated
granuloma and CD phenotype in patients with NPC1-IBD
(ﬁgure 1B), we assumed similarities in the pathogenic mechan-
ism. In CD pathogenesis, defects of antibacterial autophagy
(a process termed xenophagy) in phagocytes lead to delayed
clearance of intestinal microbiota penetrating the epithelial
barrier, which might ultimately give rise to granuloma formation
(ﬁgure 2A).34 Interestingly, recently, the lipid storage phenotype
in NPC1 neurons and hepatocytes has been associated with
impaired autophagy.35 We, therefore, investigated whether an
autophagy defect in NPC1 macrophages affects bacterial hand-
ling capacity and compared with CD in carriers of NOD2 var-
iants (ﬁgure 2A).
We developed a bacterial handling assay in MDM as macro-
phages are indispensable for granuloma formation and express
NOD2. We initially investigated to what extent prototypic
CD-associated NOD2 variants inﬂuence MDP-dependent bac-
terial killing in our gentamicin protection assay. Consistent with
previous studies,11 36 MDM from patients with IBD carrying
homozygous or two heterozygous NOD2 variants showed a
defect in MDP-dependent bacterial handling of S. typhimurium
(ﬁgure 2B, left) as well as AIEC (ﬁgure 2B, right), a strain previ-
ously implicated in CD pathogenesis.30 37 38
Interestingly, and in contrast to previously described assays that
assessed NOD2 activation in dendritic cells,11 this assay showed
an MDP-speciﬁc bacterial killing effect in healthy control MDM
that was not dependent on Toll-like receptor (TLR) or cytokine
co-stimulation (ﬁgure 2C, D). Furthermore, an inactive isomer of
MDP (ddMDP) was unable to reduce CFU and blocking of
NOD1 signalling with ML-130 (Nodinitib-1) did not inhibit bac-
terial killing, indicating that this mechanism involves NOD2
(ﬁgure 2E and see online supplementary ﬁgure S3).
Despite impaired bacterial handling in all patients with variant
NOD2, the ability to elicit an MDP-dependent cytokine response
was only affected in cells from patients expressing homozygous
1007fs but no other homozygous or compound heterozygous
NOD2 variants (ﬁgure 2F and online supplementary ﬁgure S4).
Activation of a separate NF-κB pathway with LPS resulted in
Table 1 IBD phenotype in patients with NPC
Patient
ID Sex
Age at
diagnosis of
IBD in years Diagnosis Symptoms of IBD/EIM/examination findings
Disease location,
disease behaviour,
growth delay*
Treatment for IBD: enteral
nutrition, anti-inflammatory/
immunosuppressive drugs Surgery
1 F 9.3 CD Diarrhoea, abdominal pain, rectal bleeding,
weight loss, perianal skin tags, arthritis
L2L4a, B1p
G1
CS, AB, ASA, AZA, IFX
(6-weekly)
None
2 M 32.2 IBDU Diarrhoea, rectal bleeding, weight loss No details ASA None
3 F 11 CD Diarrhoea, pain on defecation, fever, labial
abscess, perianal skin tags
L2, B1p CS, AB, ASA, AZA† None
4 F 6.2 CD Diarrhoea, perianal skin tags and fissure L2, B1p No therapy at present None
5 F 10.3 CD Diarrhoea, anogenital ulcers, perianal skin tags
and fissures
L3L4ab, B1p CS, ASA, AZA, IFX† None
6 F 7.5 CD Diarrhoea, rectal bleeding, pain on defecation,
perianal skin tags and fissures, perianal and
rectovaginal fistulae; later, cutaneous fistulae
and abscesses around stomas
L2, B3p CS, AB, NUT, ASA, IFX† End colostomy
with distal
mucus fistula
(8 years)
7 F 6.5 CD Diarrhoea, perianal skin tags Perianal disease No therapy at present None
8 F 12.4 CD Diarrhoea, rectal bleeding, pain on defecation,
perianal fissures, anorectal fistula, arthritis
L2, B1p CS, AB, NUT, ASA, IFX Operation of
fissures
9 M 3.6 IBDU Diarrhoea, iron deficiency anaemia E4
G1
NUT, AZA None
10 F 7 CD Diarrhoea, pain on defecation, perianal skin tags
and fistula
Perianal disease
11 F 15 CD Diarrhoea, abdominal pain, rectal bleeding,
weight loss, perianal skin tags and fistulae,
arthritis, skin lesions
L2, B1p
G1
CS, AB, NUT, AZA, IFX Colectomy and
ileostomy
(16 years)
12 M 30.4 CD Diarrhoea, skin lesions L2, B1 CS, ASA, IFX None
Patients 6 and 10 have been previously reported in the literature.4 31 Additional patient information based on literature only is summarised in online supplementary table S1.
*According to Paris classification.32
†Medication at time of death.
AB, oral or intravenous antibiotics given for treatment of colitis, bowel decontamination, fistula treatment; ASA, 5-aminosalicylic acid; AZA, azathioprine; CD, Crohn’s disease, CS,
corticosteroids; EIM, extraintestinal manifestations; F, female; IBDU, IBD unclassified; IFX, infliximab; M, male; NPC, Niemann–Pick disease type C; NUT, polymeric/elemental diet.
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Figure 2 Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) variants impair muramyl dipeptide (MDP)-enhanced bacterial
killing in monocyte-derived macrophages (MDM) independently of nuclear factor (NF)-κB signalling. (A) Colonic mucosa of NOD2 patients with
Crohn’s disease (CD) showing granuloma and inﬂammation (H&E stain). Enlarged view shows granuloma at higher magniﬁcation. Scale bar, 50 μm.
NOD2 protein schematic with position of the three most common variants. (B) Gentamicin protection assay with MDM obtained from IBD patients
carrying wild-type NOD2 (NOD2 wild-type (WT)), homozygous 1007 fs NOD2 (NOD2 hom 1007 fs) or other homozygous or compound heterozygous
combination of NOD2 variants (NOD2 other). Cells were pre-stimulated for 2 h with MDP before exposure to Salmonella typhimurium at an
multiplicity of infection of 10 for 1 h. Infected MDM were cultured in gentamicin-containing medium for 2 h before cell lysis and quantiﬁcation of
intracellular bacteria. Individual patient results are depicted as indicated by ticks on x-axes (left, n=9 NOD2 WT, n=3 NOD2 hom 1007fs, n=7 NOD2
other) or adherent-invasive Escherichia coli (AIEC) (right, n=4 NOD2 WT, n=4 NOD2 hom 1007 fs). For each patient, conditions were tested in three
parallel infection experiments and colony-forming units (CFU) were normalised to individual CFU without stimulation. Red bar represents mean. (C)
Gentamicin protection assay performed as in (B). MDM were pre-stimulated with MDP, LPS (100 ng/mL), interferon (IFN)-γ, interleukin (IL)-10 or
tumour necrosis factor (TNF) and exposed to S. typhimurium. Experiments were performed on four healthy controls indicated by ticks on x-axes.
Results for individual donors are shown. (D) Bacteria killing assay was performed as in (B) with healthy control MDM (n=4). Following
pre-stimulation with MDP, inactive D-D isomer MDP (ddMDP) or Pam3CSK4 (P3C), cells were infected with S. typhimurium. (E) Gentamicin
protection assay performed as in (B) with healthy control MDM (n=4). Quantiﬁcation of S. typhimurium-CFU after inhibition of NOD1 with ML-130
and MDP pre-stimulation. (F) Representative ﬂow cytometry plots and quantiﬁcation of TNF-producing HLA-DR+CD14+ monocytes after stimulation
with L18-MDP or LPS (200 ng/mL) in healthy controls (n=16) and IBD patients with wild-type NOD2 (n=11 NOD2 WT), homozygous 1007 fs NOD2
(n=4 NOD2 hom fs1007) or other homozygous or compound heterozygous combination of NOD2 variants (n=6 NOD2 other). Data represent mean
±SD. Grey background indicates normal range. p Values were throughout calculated using Mann–Whitney U test. *p<0.05, **p<0.01, ***p<0.001.
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normal levels of TNF in all tested individuals. These results indi-
cate that NOD2 variants impair bacterial degradation and have a
differential effect on cytokine responses.
XIAP-deﬁcient granulomatous IBD is associated with defects
in antibacterial autophagy
To further investigate whether defects in bacterial handling are
commonly related to granulomatous intestinal inﬂammation, we
studied individuals with loss-of-function mutations in XIAP.
Patients with XIAP deﬁciency develop CD-like ﬁstulising
intestinal inﬂammation with granuloma formation (ﬁgure
3A).17–19 XIAP-associated IBD can be cured by stem cell trans-
plantation,18 suggesting a substantial defect in the haematopoi-
etic compartment. Although XIAP is an essential transducer of
NOD2-dependent cytokine signalling,24 its role in bacterial
handling has not been studied in humans. Furthermore, infec-
tion models in XIAP-deﬁcient mice are inconclusive. Whereas
they were not susceptible to S. typhimurium infection, they
exhibited substantially decreased survival after Listeria monocy-
togenes infection.22 39
Figure 3 X-linked inhibitor of apoptosis (XIAP) and receptor-interacting kinase 2 (RIPK2) mediate activation of pro-inﬂammatory cytokines and
killing of intracellular bacteria. (A) Granulomatous colitis in XIAP deﬁciency (H&E stain). Enlarged view shows granuloma at higher magniﬁcation.
Scale bar, 50 μm. Schematic of XIAP protein indicating patient mutations. (B) Gentamicin protection assay with monocyte-derived macrophages
(MDM) from healthy controls (n=6 HC), male XIAP-deﬁcient patients (n=4 XIAP y/−) and female carriers (n=3 XIAP+/−) pre-stimulated with or
without muramyl dipeptide (MDP). Individual results are shown as indicated by ticks on x-axes. For each donor, conditions were tested in three
parallel infection experiments and colony-forming units (CFU) were normalised to individual CFU without MDP stimulation. Red bar represents mean.
(C) Representative ﬂow cytometry plots and quantiﬁcation of NOD2 and TLR4 responses in HLA-DR+CD14+ monocytes (n=5 XIAP y/−, n=3 XIAP
+/−). #Bacteria-contaminated culture medium caused high baseline production of tumour necrosis factor (TNF) in indicated patient. Mean±SD, grey
background indicates normal range. (D) Schematic of XIAP-RIPK2 interaction with small-molecule inhibitors. (E) Gentamicin protection assay
performed as in (B) with healthy control MDM. Cells were cultured in the presence or absence of XIAP-Cp-21a (1 mM) and infected with Salmonella
typhimurium (left, n=4) or adherent-invasive Escherichia coli (AIEC) (right, n=4). (F) Healthy control MDM were assayed as in (B) in the presence or
absence of ponatinib and infected with S. typhimurium (left, n=5) or AIEC (right, n=4). (G) Induction of TNF in healthy donor monocytes
pre-incubated with the XIAP-Cp-21a (1 μM) or ponatinib and activated with L18-MDP or LPS (100 ng/mL). (H) Puriﬁcation of endogenous ubiquitin
(Ub) conjugates using tandem ubiquitin binding entities (TUBE) in lysates of MDM pretreated with XIAP-Cp-21a. Puriﬁed material and lysate was
examined by immunoblotting for the indicated proteins. p Values were throughout determined using Mann–Whitney U test. *p<0.05, **p<0.01,
***p<0.001.
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Due to the X-linked inheritance, we obtained MDM from
XIAP-deﬁcient males and female carriers of XIAP-defects. All
mutations disrupted XIAP’s C-terminal RING domain, which
confers Ub-ligase activity (ﬁgure 3A).23 As shown in ﬁgure 3B,
C, XIAP-deﬁcient macrophages failed to kill bacteria in an
MDP-dependent manner and showed disrupted TNF induction.
In contrast, female carriers of a defective XIAP gene showed
normal TNF production and normal bacterial handling (ﬁgure
3B, C). Under constitutive conditions, bacterial handling in
XIAP-deﬁcient macrophages did not differ from healthy con-
trols (data not shown).
One mutational hotspot in XIAP-deﬁcient patients is the BIR2
domain that mediates binding of XIAP to the adapter kinase
RIPK2.24 To mimic the functional consequences of mutations
in the XIAP-BIR2 domain, we used compound 21a
(XIAP-Cp-21a), which selectively targets this domain (ﬁgure
3D).28 Accordingly, XIAP-Cp-21a impaired MDP-dependent
bacterial killing and TNF production to a similar extent as
observed in XIAP-deﬁcient males (ﬁgure 3B, E). XIAP-Cp-21a
directly interfered with initial pathway activation and impaired
MDP-induced RIPK2 ubiquitination (ﬁgure 3H).
Since NOD2 and XIAP functionally converge on the adapter
kinase RIPK2, we next investigated its role for bacterial killing
in macrophages using the RIPK2 tyrosine kinase inhibitor pona-
tinib.40 41 Consistent with a role of RIPK2 as part of the
NOD2-XIAP complex, ponatinib completely abrogated
MDP-induced TNF production and bacterial killing but showed
no effect on LPS-dependent TNF upregulation (ﬁgure 3F, G).
The lysosomal storage disease NPC1 impairs bacterial
handling in macrophages
Since bacterial handling is defective in classical NOD2-CD and
XIAP-associated CD, we evaluated whether lysosomal lipid
storage affects bacterial handling in MDM of patients with
NPC1 or MDM with pharmacologically induced NPC1 storage
phenotype.
Primary NPC1 patient MDM showed enlarged lysosomes and
the efﬁciency of MDP-dependent bacterial killing was dimin-
ished (ﬁgure 4A, B and online supplementary ﬁgure S5). This
defect was evident for S. typhimurium (ﬁgure 4B, left) and, to a
lesser extent, for AIEC (ﬁgure 4B, right). To verify our results,
we modelled the NPC1 phenotype in vitro. Culture of MDM in
the presence of U18666A for 48 h causes an accumulation of
lipids in the late endosomal and lysosomal compartment2 and
phenocopies the lipid storage disease (ﬁgure 4A). In our MDM
bacterial handling assay, U18666A treatment increased baseline
level of intracellular bacteria compared with untreated MDM
and impaired MDP-mediated control of bacteria (ﬁgure 4C).
To investigate whether the impaired bacterial handling was
due to defective NOD2 signal initiation, we tested the response
to MDP by ﬂow cytometry. Defects in NPC1 did neither abro-
gate NOD2 nor TLR signalling (ﬁgure 4D) nor was the stimula-
tion affected by miglustat (see online supplementary ﬁgure S6).
Indeed, stimulation of U18666A-treated cells with bacterial
ligands led to an enhanced production of pro-inﬂammatory
cytokines (ﬁgure 4D and online supplementary ﬁgure S7).
Furthermore, we observed functional ubiquitination of RIPK2
in U18666A-treated MDM, indicating that the signalling
complex formed by NOD2-RIPK2-XIAP is functionally intact
(ﬁgure 4E).
Altogether, these data suggest that NOD2-RIPK2-XIAP form a
signal initiation complex in macrophages, leading to RIPK2
ubiquitination and subsequent activation of downstream NF-κB
signalling as indicated by TNF expression as well as innate
immunity against intracellular pathogens. However, NPC1
mutations cause a defect in bacterial handling, including
NOD2-mediated xenophagy without affecting NOD2-dependent
TNF expression.
Defective autophagy in NPC1 impairs clearance of
intracellular bacteria
This prompted us to investigate the mechanism of bacterial
handling defect in patients with NPC1. We ﬁrst excluded differ-
ences in bacterial uptake of GFP-expressing S. typhimurium
(GFP-S. typhimurium) in U18666A-MDM and untreated-MDM
and found similar infection rates (ﬁgure 5A, left). However, in
U18666A-MDM, the GFP signal increased with time, indicating
normal phagocytosis but conﬁrming increased bacterial survival
(ﬁgure 5A, right). Similarly, there was no difference in uptake of
non-viable fragmented E. coli particles within 1 h (see online
Figure 3 Continued
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supplementary ﬁgure S8). As E. coli and S. typhimurium have
been shown to be sensitive to bacterial killing mediated by react-
ive oxygen species (ROS), we also excluded differences in the
production of ROS after phorbol myristate acetate (PMA) stimu-
lation (see online supplementary ﬁgure S9).
We next investigated whether the deregulation of autophagy
affects NPC1 macrophage function. Of note, treatment with
U18666A blocked steady-state autophagic ﬂux in MDM, indi-
cated by increased LC3 levels and decreased clearance of the
autophagy substrate p62, which persisted even after exposure to
S. typhimurium (ﬁgure 5B and online supplementary ﬁgure
S10). This is consistent with ﬁndings in human and mouse
NPC1 ﬁbroblasts,35 showing increased LC3 punctuation sug-
gestive of impaired maturation of autophagy-related vesicles (see
online supplementary ﬁgure S11). This ﬂux defect was not
reversed by miglustat treatment (see online supplementary
ﬁgure S11). Since lysosomal biogenesis and autophagy are also
transcriptionally regulated, we investigated whether the major
regulator transcription factor EB (TFEB) contributes to dysregu-
lated autophagy. We found normal lysosomal biogenesis and
nuclear translocation of TFEB in primary NPC1 ﬁbroblasts and
MDM with U18666A-induced storage phenotype, suggesting
that this pathway does not play a major role (see online
supplementary ﬁgure S12).
To gain further mechanistic insight, we infected MDM
obtained from patients with NPC1and healthy controls with
GFP-S. typhimurium and stained lysosomes with Lysotracker
(LT) probe and cellular or bacterial DNA with 40,6-diamidino-2-
phenylindole (DAPI) (ﬁgure 5C). Consistent with previous
results, NPC1 mutant MDM contained substantially more intra-
cellular bacteria (ﬁgure 5D). Since bacteria lose their GFP signal
in lysosomes, bacterial DAPI staining allowed continuous
Figure 4 Niemann–Pick disease type C1 (NPC1) lysosomal lipid storage disease causes ineffective pathogen clearance despite functional cytokine
pathways. (A) Lysosomal lipid storage phenotype in vehicle-treated, U18666A-treated and primary NPC1 monocyte-derived macrophages (MDM).
Scale bar, 5 mm. (B) Bacterial killing assay with healthy (n=4–5) and NPC1 patient (n=3–4) MDM and infected with Salmonella typhimurium (left)
or adherent-invasive Escherichia coli (AIEC) (right). Individual results are shown as indicated by ticks on x-axes. For each donor, conditions were
tested in three parallel infection experiments and colony-forming units (CFU) were normalised to individual CFU without muramyl dipeptide (MDP)
stimulation. Red bar represents mean. (C) Cells were assayed as in (B). MDM treated with or without U18666A and MDP pre-stimulation were
exposed to S. typhimurium (left, n=4) or AIEC (right, n=4). (D) Representative ﬂow cytometry plots and quantiﬁcation of tumour necrosis factor
(TNF) response in primary NPC1 (n=5) or U18666A-treated (n=4) HLA-DR+CD14+ monocytes following NOD2 or TLR4 stimulation. Mean±SD, grey
background indicates normal range calculated from all measured healthy donors. (E) Puriﬁcation of endogenous ubiquitin (Ub) conjugates using
tandem ubiquitin binding entities (TUBE) in lysates of U18666A-treated and control MDM. Puriﬁed material and lysate was examined by
immunoblotting for indicated proteins. p Values were throughout calculated using Mann–Whitney U test. *p<0.05, **p<0.01, ***p<0.001.
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tracking of bacteria through different stages of degradation
(ﬁgure 5E). We classiﬁed intracellular bacteria according to GFP
and LT ﬂuorescence and distinguished between four groups: (1)
live GFP+ bacteria, (2) non-degraded GFP+ bacteria localising
to lysosomes, (3) degraded GFP-bacteria localising to lysosomes
and (4) DAPI+ bacterial remnants. In macrophages obtained
from NPC1 patients, we observed signiﬁcantly more live GFP+
bacteria that do not localise to lysosomes (ﬁgure 5F, G).
We initially assumed the reduced bacterial killing could be
due to defective autophagosome-lysosome fusion and expected
an increased number of LC3-decorated bacteria in the presence
of defective lipid loaded lysosomes that do not fuse.
Figure 5 Increased bacterial colonisation of Niemann–Pick disease type C1 (NPC1) macrophages is caused by impaired antibacterial autophagy.
(A) Flow cytometric analysis of green ﬂuorescent protein (GFP) signal in healthy control monocyte-derived macrophages (MDM) treated with or
without U18666A and challenged with GFP-Salmonella typhimurium for 1 h (infection, left) or incubated for one additional hour with
gentamicin-containing medium (bacterial clearance, right). External bacteria were quenched with trypan blue. (B) Healthy control MDM were treated
with or without U18666A followed by immunoblotting with anti-LC3, anti-p62 and anti-actin. Protein levels of LC3 and p62 were semi-quantiﬁed by
densitometry relative to actin and expressed as per cent increase to vehicle-treated condition. (C–G) Primary NPC1 mutant and healthy control MDM
were infected with GFP-S. typhimurium for 1 h, followed by 1 h culture in gentamicin-containing medium supplemented with Lysotracker (LT) and
DAPI staining. Analysis is based on MDM from two patients with NPC1 and four healthy donors. (C) Representative images of infected
macrophages. Scale bar, 5 μm. (D) Quantiﬁcation of total number of bacteria per macrophage. (E) Microscopic assessment of GFP-S. typhimurium
according to co-localisation with lysosomes. (F) Percentage of bacteria found in the different stages of autophagic degradation. (G) Absolute
numbers of bacteria per MDM for indicated groups. (H) Infection experiment performed as in (C). Additionally, following ﬁxation, MDM were stained
with anti-LC3 and co-localisation with bacteria quantiﬁed by confocal microscopy. (I) Analysis of LC3-decorated bacteria in primary NPC1 mutant
MDM (blue symbol) compared with healthy donor MDM (n=2) or MDM treated with or without U18666A (n=4). Each symbol represents one
individual. p Values were determined by Mann–Whitney U test. *p<0.05, **p<0.01, ***p<0.001.
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Unexpectedly, in U18666A-MDM or primary NPC1 mutant
MDM signiﬁcantly fewer bacteria were LC3-labelled (ﬁgure
5H, I), whereas in WT-macrophages, a substantial number of
intracellular bacteria can be found in LC3-associated vesicles
indicative of antibacterial autophagy (ﬁgure 5H, I). This sug-
gested that the defect in NPC1 impairs a critical stage of
phagosome-autophagosome transition between bacterial sensing
and bacterial degradation. Indeed, proteomic raw data of
isolated phagosomes suggest that NPC1 is already expressed in
early phagosomes of human and murine phagocytes.42–44
Induction of autophagy rescues bacterial handling in NPC1
Potential treatment strategies for the neurodegenerative disease
NPC1 focused until recently on the depletion of cholesterol
from the lysosomal/late-endosomal compartment, for example,
by means of HP-β-cyclodextrin (HPβCD).45 HPβCD has been
Figure 5 Continued
Figure 6 Induction of autophagy with chlorpromazine overcomes bacterial killing defect in Niemann–Pick disease type C1 (NPC1). (A)
U18666A-treated monocyte-derived macrophages (MDM) were cultured in 0.5–2% of HP-β-cyclodextrin (HPβCD) for last 24 h of U18666A treatment
(48 h) and stained with Lysotracker red. Scale bar, 5 μm. (B) Gentamicin protection assay in vehicle- or U18666A-MDM pre-treated with
chlorpromazine for 3 h before infection with Salmonella typhimurium, n=4. Treatment of U18666A-MDM with 2% HPβCD was performed for last
24 h in the presence of U18666A (48 h). Individual results are shown as indicated by ticks on x-axes. For each donor, experimental conditions were
tested in three parallel infection experiments and colony-forming units (CFU) were normalised to individual vehicle-treated control. Red bar
represents mean. p Values were determined by Mann–Whitney U test comparing results to vehicle-treated control, ***p<0.001. (C)
Immunoﬂuorescence staining with anti-LC3 of untreated or U18666A-treated MDM pre-incubated with chlorpromazine for 3 h before exposure to
green ﬂuorescent protein (GFP)-S. typhimurium. Scale bar, 5 μm. Quantiﬁcation of LC3-decorated bacteria in chlorpromazine conditions was
performed in one representative experiment.
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used successfully to treat neuron lysosomal storage in vitro and in
vivo. Since HPβCD does not pass the blood–brain barrier, we
reasoned that it might be a peripherally acting agent beneﬁcial
for restoring macrophage function. As expected, HPβCD
reduced the lysosomal volume of U18666A-MDM dose-
dependently (ﬁgure 6A). However, despite effective cholesterol
depletion and normalisation of the lysosomal volume in cells,
this treatment did not rescue the dysfunctional bacterial handling
in U18666A-MDM (ﬁgure 6B). Most recently, autophagy induc-
tion was suggested as a therapeutic strategy for IBD and neurode-
generative diseases.46 47 We observed that treatment of
U18666A-MDM with the autophagy enhancer chlorpromazine
restored the defect in autophagic ﬂux and resulted in normal bac-
terial degradation (ﬁgure 6B). Treatment of human MDM with
chlorpromazine led to dose-dependent increase in LC3-mediated
bacterial clearance (ﬁgure 6B, C). The differential effects of
HPβCD versus chlorpromazine in macrophages argue again for a
critical role of NPC1 in autophagy, affecting autophagosome
function upstream of the lysosomal storage defect. Other indu-
cers of autophagy, like rapamycin11 or trehalose,48 did either not
improve bacterial handling in U18666A-MDM or were asso-
ciated with substantial pro-inﬂammatory cytokine induction (see
online supplementary ﬁgure S13).
DISCUSSION
We identify a group of patients with NPC1 mutations who
develop severe early-onset CD-like intestinal inﬂammation with
granuloma formation and perianal disease that cannot be
Figure 7 Summary ﬁgure and graphical abstract. (A) Summary ﬁgure of tumour necrosis factor (TNF) response and bacterial killing following
activation of nucleotide-binding oligomerization domain-containing protein 2 (NOD2) pathway. Data represent mean±SD of results obtained from
patients or inhibitors. (B) Graphical abstract summarising the functional mechanisms. NOD2-RIPK2-XIAP complex activates NF-κB-dependent
signalling pathways (1) and induces clearance of cytosolic bacteria that requires functional autophagic-lysosomal interplay (2). Failure in prompt
removal of invading bacteria may result in accumulation of bacteria leading to chronic stimulation of pattern-recognition receptors (eg, TLR4) by
bacterial products causing a net NF-κB activation and consequently chronic inﬂammation (3). WT, wild-type.
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distinguished from CD. We provide a mechanism of impaired
bacterial handling in NPC1 that conceptually links NPC1-IBD
to other genetic defects associated with granulomatous intestinal
inﬂammation, NOD2 and XIAP. We conﬁrm that XIAP deﬁ-
ciency, a cause of monogenic IBD with granuloma, does disrupt
NOD2-mediated cytokine production17–19 and provide novel
evidence that it disturbs NOD2-dependent xenophagy. Whereas
mutations in NOD2 and XIAP impair the initiation of autopha-
gic elimination of intracellular bacteria, NPC1 impairs autopha-
gosome function (ﬁgure 7A). Although these molecules act at
different checkpoints along the antibacterial autophagy or cyto-
kine pathway (ﬁgure 7B), genetic variation in NOD2, XIAP and
NPC1 results in a similar intestinal phenotype. Thus, heteroge-
neous genetic defects highlight bacterial handling as a likely
defect of general importance in CD immune-pathogenesis with
multiple cassettes or pathways contributing.
There is good genetic evidence that susceptibility to polygenic
CD is associated with several common variants affecting
autophagy.49 Variants in NOD2 functionally link bacterial
recognition to selective antimicrobial autophagy involving
ATG16L1.11 13 36 50 Whereas previous studies might have pre-
dicted the effect of XIAP deﬁciency on NOD2-dependent xeno-
phagy, the link to NPC1 represents a novel IBD susceptibility
gene. Although spontaneous colitis has not been described in
animal models of NPC, several reasons suggest causality in
human NPC1-IBD rather than mere coincidence: (1) the associ-
ation of NPC1 with CD-like immunopathology but not UC, (2)
the early paediatric onset of symptoms with severe phenotype
and (3) the reproducible ﬁnding among many centres making a
reporting bias very unlikely.
Based on large cohort of patients with NPC in Manchester
with approximately 150 patients, we were able to estimate a 3–
7% penetrance of IBD in patients with NPC. Although this
seems low, it should be seen in perspective that the penetrance
of IBD in patients with one of the three most common NOD2
mutations (homozygous and compound heterozygous) is only
about 1.5%.51 Indeed, as patients with NPC1 have a shorter life
expectancy,1 the true impact of NPC1 deﬁciency for the devel-
opment of IBD may have even been underestimated.
Based on our studies of three different human genotypes with
CD-like immunopathology, we dissected MDP-dependent
cytokine signalling and bacterial killing, which are parallel
and partially independent pathways downstream of the
NOD2-RIPK2-XIAP initiation complex. Indeed, loss of function
in NPC1 impairs the control of bacterial handling without loss
of NF-κB-driven cytokine release. Our data imply that defects
in NPC1 impair the process of steady-state autophagosome mat-
uration and affect autophagic trafﬁcking of bacteria to lysosomes
in macrophages. Since bacteria do not accumulate in LC3+
autophagosomes, we speculate that NPC1 might be involved
upstream in phagosome-autophagosome transition. This mech-
anism becomes more obvious in the defence against S. typhi-
murium compared with AIEC since S. typhimurium is a
facultative intracellular pathogen and clearance from the host
strongly depends on autophagy.52 53 The described immune dys-
function extents the role of NPC1 for autophagy beyond
hepatic or neuronal cell defects with lipid storage disease.35 54
Our results suggest that excessive inﬂammation seen in IBD is
not only a result of dysfunctional NF-κB signalling in macro-
phages but secondary due to insufﬁcient removal of intruding
bacteria. As a functional consequence, these pathogens serve as
a constant stimulus on other pattern recognition receptors with
intact signalling cascades, for example, toll-like receptors that
ﬁnally lead to increased cytokine production. Current treatment
strategies in CD aim to suppress this active inﬂammation and
use immunosuppressive strategies to maintain remission.55 Our
data provide a strong rationale to develop drugs that target the
defective bacterial defence and enhance macrophage clearance
function. We used chlorpromazine since macrophages are rela-
tive insensitive to rapamycin56 and our preliminary data suggest
that these drugs have a different mechanism of action.
Chlorpromazine represents a group of autophagy inducers that
includes several US Food and Drug Administration-approved
drugs57 and has previously been identiﬁed to improve cellular
defence against intracellular bacteria in mouse bone marrow-
derived macrophages.58 The mechanism of action for chlorpro-
mazine and the related group of autophagy-inducing substances
with a joint N10-substituted phenoxazine scaffold needs to be
clariﬁed. It will be interesting to evaluate whether
autophagy-inducing therapies have effects during active inﬂam-
mation or rather in maintaining remission.
In conclusion, our data imply that impaired bacterial handling
underlies several genetic defects associated with granulomatous
colitis and therapeutic modiﬁcation of bacterial handling is a
potential treatment option in IBD.
Author afﬁliations
1Translational Gastroenterology Unit, University of Oxford, Oxford, UK
2Nufﬁeld Department of Clinical Medicine, Ludwig Institute for Cancer Research,
University of Oxford, Oxford, UK
3Willink Biochemical Genetics Unit, Manchester Centre for Genomic Medicine, Saint
Mary’s Hospital, Manchester, UK
4National Hospital for Neurology and Neurosurgery, London, UK
5Great Ormond Street Hospital, London, UK
6NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
7Department of Clinical Immunology, Great Ormond Street Hospital, London, UK
8University of Heidelberg, Heidelberg, Germany
9University Children’s Hospital Bonn, Bonn, Germany
10Children’s Hospital Münster, Münster, Germany
11Children’s Research Centre Zurich, University Children’s Hospital, Zurich,
Switzerland
12Division of Pediatric Gastroenterology, Emory University School of Medicine,
Atlanta, Georgia, USA
13SickKids Inﬂammatory Bowel Disease Center and Cell Biology Program, Research
Institute, The Hospital for Sick Children, Toronto, Ontario, Canada
14Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics,
The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
15Department of Pharmacology, University of Oxford, Oxford, UK
16Dr. von Hauner Children’s Hospital, Ludwig-Maximilians-University, Munich,
Germany
17Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
18Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
19Department of Pediatrics, University of Oxford, Oxford, UK
Acknowledgements The authors thank all patients and their families for
participation in this study. They would like to thank all contributors of the Oxford
IBD cohort study. The authors also thank T Steevels and A Simmons for helpful
discussions and TetraLogic Pharmaceuticals for providing compounds and advice.
MRI image was provided courtesy of Department of Clinical Radiology (W Heindel),
University Hospital Muenster, Germany. Salmonella enterica serovar typhimurium (S.
typhimurium)-expressing GFP was kindly provided by D Holden (Imperial College,
University of London, UK) and adherent-invasive E. coli reference strain LF82 (AIEC)
was a kind gift from A Darfeuille-Michaud (Clermont Université, Clermont-Ferrand,
France). TFEB-3×FLAG RAW264.7 cells were a kind gift from M Ferron and G
Karsenty (Columbia University Medical Center, New York, USA) and kindly provided
by J Irazoqui (Center for the Study of Inﬂammatory Bowel Disease, Boston, USA).
Data were kindly provided by the FDA and H J Chen (ehealthMe database). J E
Wraith as well as A Darfeuille-Michaud sadly passed over the period of the study.
Contributors HHU and FMP coordinated the research. JEW made the clinical
observation that NPC1 patients develop intestinal inﬂammation. TS, H-TY, SP, KB
and JJ performed experiments and analysed the data. JEW, EJ, RHL, NS, SYP, HC,
CB, HR, GD, RB, MR, SKu, SKe, AE, AMM, SKo and TM provided clinical data or
patient samples. The ﬁrst version of the manuscript was written by TS and HHU. FP,
NP, RJX, FMP and MG-H provided conceptual advice. All authors corrected the
manuscript. JEW gave interim and all other authors gave ﬁnal approval to it.
12 Schwerd T, et al. Gut 2016;0:1–14. doi:10.1136/gutjnl-2015-310382
Inﬂammatory bowel disease
group.bmj.com on January 31, 2017 - Published by http://gut.bmj.com/Downloaded from 
Funding The work was initiated by an ESPGHAN exchange program 2011 to TS,
SKo and HHU. TS is supported by the Deutsche Forschungsgemeinschaft
(SCHW1730/1-1). HHU, FP and RJX are supported by the Crohn’s & Colitis
Foundation of America (CCFA) and FP, HHU and AMM by The Leona M. and Harry
B. Helmsley Charitable Trust. HHU is supported by ForCrohns/Crohns and Colitis UK
and ESPGHAN and SP by a Boehringer Ingelheim Foundation grant. FP is supported
by the Wellcome Trust. MG-H is supported by a Wellcome Trust Fellowship (102894/
Z/13/Z), Ludwig Cancer Research and a Sapere Aude: Danish Council for
independent Research-Starting Grant. RHL was supported by the National Institute
for Health Research University College London Hospitals Biomedical Research Centre.
SYP is supported by the NIHR Oxford Biomedical Research Centre. FMP is a Royal
Society Wolfson Research Merit Award holder. SKe is supported by the NIHR Oxford
Comprehensive Biomedical Research Centre.
Competing interests HHU declares industrial project collaboration with Lilly, UCB
Pharma and Vertex Pharmaceuticals. Travel support was received from Essex Pharma,
Actelion, and MSD. FMP is a consultant to Actelion. TS received speaker’s fees from
MSD and travel support from Nestlé Nutrition. RHL received honorary and consulting
fees from Actelion.
Patient consent Informed consent was obtained from all healthy donors, patients
or their parents. Written informed consent (or parental permission and child assent)
was obtained from all participants before their involvement.
Ethics approval Studies were approved by institutional review boards as part of
the Oxford IBD cohort study and a subproject to investigate monogenic diseases.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Compound 21a was obtained from TetraLogic
Pharmaceuticals through an MTA.
Open Access This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/
REFERENCES
1 Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis 2010;5:16.
2 Lloyd-Evans E, Morgan AJ, He X, et al. Niemann-Pick disease type C1 is a
sphingosine storage disease that causes deregulation of lysosomal calcium.
Nat Med 2008;14:1247–55.
3 Walterfang M, Chien YH, Imrie J, et al. Dysphagia as a risk factor for mortality in
Niemann-Pick disease type C: systematic literature review and evidence from studies
with miglustat. Orphanet J Rare Dis 2012;7:76.
4 Patterson MC, Vecchio D, Jacklin E, et al. Long-term miglustat therapy in children
with Niemann-Pick disease type C. J Child Neurol 2010;25:300–5.
5 Héron B, Valayannopoulos V, Baruteau J, et al. Miglustat therapy in the French
cohort of paediatric patients with Niemann-Pick disease type C. Orphanet J Rare
Dis 2012;7:36.
6 Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inﬂammatory
bowel disease. Nature 2011;474:298–306.
7 Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inﬂammatory bowel
disease. Nature 2011;474:307–17.
8 Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the
genetic architecture of inﬂammatory bowel disease. Nature 2012;491:119–24.
9 Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat
variants with susceptibility to Crohn’s disease. Nature 2001;411:599–603.
10 Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated
with susceptibility to Crohn’s disease. Nature 2001;411:603–6.
11 Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic
cells inﬂuencing bacterial handling and antigen presentation. Nat Med
2010;16:90–7.
12 Hisamatsu T, Suzuki M, Reinecker HC, et al. CARD15/NOD2 functions as an
antibacterial factor in human intestinal epithelial cells. Gastroenterology
2003;124:993–1000.
13 Philpott DJ, Sorbara MT, Robertson SJ, et al. NOD proteins: regulators of
inﬂammation in health and disease. Nat Rev Immunol 2014;14:9–23.
14 Uhlig HH. Monogenic diseases associated with intestinal inﬂammation: implications
for the understanding of inﬂammatory bowel disease. Gut 2013;62:1795–805.
15 Uhlig HH, Schwerd T, Koletzko S, et al. The diagnostic approach to monogenic very
early onset inﬂammatory bowel disease. Gastroenterology 2014;147:990–1007.e3.
16 Uhlig HH, Schwerd T. From genes to mechanisms: the expanding spectrum of
monogenic disorders associated with inﬂammatory bowel disease. Inﬂamm Bowel
Dis 2016;22:202–12.
17 Aguilar C, Lenoir C, Lambert N, et al. Characterization of Crohn disease in X-linked
inhibitor of apoptosis-deﬁcient male patients and female symptomatic carriers.
J Allergy Clin Immunol 2014;134:1131–41.e9.
18 Speckmann C, Ehl S. XIAP deﬁciency is a mendelian cause of late-onset IBD. Gut
2014;63:1031–2.
19 Zeissig Y, Petersen BS, Milutinovic S, et al. XIAP variants in male Crohn’s disease.
Gut 2015;64:66–76.
20 Rigaud S, Fondanèche MC, Lambert N, et al. XIAP deﬁciency in humans causes an
X-linked lymphoproliferative syndrome. Nature 2006;444:110–14.
21 Krieg A, Correa RG, Garrison JB, et al. XIAP mediates NOD signaling via interaction
with RIP2. Proc Natl Acad Sci U S A 2009;106:14524–9.
22 Bauler LD, Duckett CS, O’Riordan MX. XIAP regulates cytosol-speciﬁc innate
immunity to Listeria infection. PLoS Pathog 2008;4:e1000142.
23 Damgaard RB, Nachbur U, Yabal M, et al. The ubiquitin ligase XIAP recruits LUBAC
for NOD2 signaling in inﬂammation and innate immunity. Mol Cell 2012;46:746–58.
24 Damgaard RB, Fiil BK, Speckmann C, et al. Disease-causing mutations in the XIAP
BIR2 domain impair NOD2-dependent immune signalling. EMBO Mol Med
2013;5:1278–95.
25 Fiil BK, Damgaard RB, Wagner SA, et al. OTULIN restricts Met1-linked
ubiquitination to control innate immune signaling. Mol Cell 2013;50:818–30.
26 Vince JE, Wong WW, Khan N, et al. IAP antagonists target cIAP1 to induce
TNFalpha-dependent apoptosis. Cell 2007;131:682–93.
27 Condon SM, Mitsuuchi Y, Deng Y, et al. Birinapant, a smac-mimetic with improved
tolerability for the treatment of solid tumors and hematological malignancies. J Med
Chem 2014;57:3666–77.
28 Kester RF, Donnell AF, Lou Y, et al. Optimization of benzodiazepinones as selective
inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus
IAP repeat (BIR2) domain. J Med Chem 2013;56:7788–803.
29 Ammann S, Elling R, Gyrd-Hansen M, et al. A new functional assay for the
diagnosis of X-linked inhibitor of apoptosis (XIAP) deﬁciency. Clin Exp Immunol
2014;176:394–400.
30 Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of
adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease.
Gastroenterology 2004;127:412–21.
31 Steven LC, Driver CP. Niemann-pick disease type C and Crohn’s disease. Scott Med
J 2005;50:80–1.
32 Levine A, Grifﬁths A, Markowitz J, et al. Pediatric modiﬁcation of the Montreal
classiﬁcation for inﬂammatory bowel disease: the Paris classiﬁcation. Inﬂamm Bowel
Dis 2011;17:1314–21.
33 Patterson MC, Vecchio D, Prady H, et al. Miglustat for treatment of Niemann-Pick C
disease: a randomised controlled study. Lancet Neurol 2007;6:765–72.
34 Petersen HJ, Smith AM. The role of the innate immune system in granulomatous
disorders. Front Immunol 2013;4:120.
35 Sarkar S, Carroll B, Buganim Y, et al. Impaired autophagy in the lipid-storage
disorder Niemann-Pick type C1 disease. Cell Rep 2013;5:1302–15.
36 Homer CR, Richmond AL, Rebert NA, et al. ATG16L1 and NOD2 interact in an
autophagy-dependent antibacterial pathway implicated in Crohn’s disease
pathogenesis. Gastroenterology 2010;139:1630–41, 41.e1–2.
37 Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia
coli strains in ileal mucosa of patients with Crohn’s disease. Gastroenterology
1998;115:1405–13.
38 Lapaquette P, Bringer MA, Darfeuille-Michaud A. Defects in autophagy favour
adherent-invasive Escherichia coli persistence within macrophages leading to
increased pro-inﬂammatory response. Cell Microbiol 2012;14:791–807.
39 Prakash H, Albrecht M, Becker D, et al. Deﬁciency of XIAP leads to sensitization for
Chlamydophila pneumoniae pulmonary infection and dysregulation of innate
immune response in mice. J Biol Chem 2010;285:20291–302.
40 Tigno-Aranjuez JT, Asara JM, Abbott DW. Inhibition of RIP2’s tyrosine kinase activity
limits NOD2-driven cytokine responses. Genes Dev 2010;24:2666–77.
41 Canning P, Ruan Q, Schwerd T, et al. Inﬂammatory Signaling by NOD-RIPK2 Is
Inhibited by Clinically Relevant Type II Kinase Inhibitors. Chem Biol
2015;22:1174–84.
42 Dill BD, Gierlinski M, Härtlova A, et al. Quantitative proteome analysis of temporally
resolved phagosomes following uptake via key phagocytic receptors. Mol Cell
Proteomics 2015;14:1334–49.
43 Buschow SI, Lasonder E, Szklarczyk R, et al. Unraveling the human dendritic cell
phagosome proteome by organellar enrichment ranking. J Proteomics
2012;75:1547–62.
44 Lee BY, Jethwaney D, Schilling B, et al. The Mycobacterium bovis bacille
Calmette-Guerin phagosome proteome. Mol Cell Proteomics 2010;9:32–53.
45 Rosenbaum AI, Maxﬁeld FR. Niemann-Pick type C disease: molecular mechanisms
and potential therapeutic approaches. J Neurochem 2011;116:789–95.
46 Menzies FM, Fleming A, Rubinsztein DC. Compromised autophagy and
neurodegenerative diseases. Nat Rev Neurosci 2015;16:345–57.
47 Nys K, Agostinis P, Vermeire S. Autophagy: a new target or an old strategy for the
treatment of Crohn’s disease? Nat Rev Gastroenterol Hepatol 2013;10:395–401.
48 Sarkar S, Davies JE, Huang Z, et al. Trehalose, a novel mTOR-independent
autophagy enhancer, accelerates the clearance of mutant huntingtin and
alpha-synuclein. J Biol Chem 2007;282:5641–52.
49 Van Limbergen J, Radford-Smith G, Satsangi J. Advances in IBD genetics. Nat Rev
Gastroenterol Hepatol 2014;11:372–85.
Schwerd T, et al. Gut 2016;0:1–14. doi:10.1136/gutjnl-2015-310382 13
Inﬂammatory bowel disease
group.bmj.com on January 31, 2017 - Published by http://gut.bmj.com/Downloaded from 
50 Travassos LH, Carneiro LA, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by
recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat
Immunol 2010;11:55–62.
51 Yazdanyar S, Kamstrup PR, Tybjaerg-Hansen A, et al. Penetrance of NOD2/CARD15
genetic variants in the general population. CMAJ 2010;182:661–5.
52 Malik-Kale P, Jolly CE, Lathrop S, et al. Salmonella—at home in the host cell. Front
Microbiol 2011;2:125.
53 Paulus GL, Xavier RJ. Autophagy and checkpoints for intracellular pathogen
defense. Curr Opin Gastroenterol 2015;31:14–23.
54 Maetzel D, Sarkar S, Wang H, et al. Genetic and chemical correction of cholesterol
accumulation and impaired autophagy in hepatic and neural cells derived from
Niemann-Pick Type C patient-speciﬁc iPS cells. Stem Cell Reports 2014;2:866–80.
55 Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based
Consensus on the diagnosis and management of Crohn’s disease: Current
management. J Crohns Colitis 2010;4:28–62.
56 Woltman AM, de Fijter JW, Kamerling SW, et al. Rapamycin induces apoptosis in
monocyte- and CD34-derived dendritic cells but not in monocytes and
macrophages. Blood 2001;98:174–80.
57 Tsvetkov AS, Miller J, Arrasate M, et al. A small-molecule scaffold induces
autophagy in primary neurons and protects against toxicity in a Huntington disease
model. Proc Natl Acad Sci U S A 2010;107:16982–7.
58 Shaw SY, Tran K, Castoreno AB, et al. Selective modulation of autophagy, innate
immunity, and adaptive immunity by small molecules. ACS Chem Biol
2013;8:2724–33.
14 Schwerd T, et al. Gut 2016;0:1–14. doi:10.1136/gutjnl-2015-310382
Inﬂammatory bowel disease
group.bmj.com on January 31, 2017 - Published by http://gut.bmj.com/Downloaded from 
disease
deficiency with NOD2 variants in Crohn's 
Pick disease type C1 and XIAP−Niemann
 granulomatous intestinal inflammation in
 Impaired antibacterial autophagy links
Frances M Platt and Holm H Uhlig
Thorsten Marquardt, Fiona Powrie, James E Wraith, Mads Gyrd-Hansen, 
Elkadri, Nick Platt, Alexio M Muise, Sibylle Koletzko, Ramnik J Xavier,
Rohrbach, Subra Kugathasan, Helen Chapel, Satish Keshav, Abdul 
MarianneY Patel, Claire Booth, Heiko Runz, Gesche Düker, Ruth Bettels, 
SmitaElisabeth Jameson, Jonathan Jung, Robin H Lachmann, Neil Shah, 
Tobias Schwerd, Sumeet Pandey, Huei-Ting Yang, Katrin Bagola,
 published online March 7, 2016Gut 
 http://gut.bmj.com/content/early/2016/03/07/gutjnl-2015-310382
Updated information and services can be found at: 
These include:
References
#BIBLhttp://gut.bmj.com/content/early/2016/03/07/gutjnl-2015-310382
This article cites 58 articles, 16 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (932)Crohn's disease
 (327)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on January 31, 2017 - Published by http://gut.bmj.com/Downloaded from 
